their lateral aggregation, thick fibrin fibers are crosslinked in a reaction catalyzed by thrombin activated factor XIII.
1 Fibrin, together with plate lets and red blood cells, provide structural in tegrity to the hemostatic plug under physiolog ical conditions and to the growing thrombus in thrombotic disorders.
The final fibrin clot has a highly heterogeneous structure, determined by genetic and, to a much larger extent, environmental factors, which re sults in a large interindividual variability of clot architecture, thickness of fibers, and their branch ing. 2 Lower fibrinogen concentrations are known to result in the formation of thicker fibrin fibers creating looser meshwork which is more suscep tible to fibrinolysis and mechanical fragmenta tion, eventually leading to an increased risk of bleeding. On the other hand, irregular abnormal Fibrinogen structure Fibrinogen is a 340 kDa pro tein synthesized in the liver.
1 Its normal con centration in blood plasma is in the range of 1.5 to 4.0 g/l. The half life of circulating fibrin ogen is about 3 to 4 days. The fibrinogen mole cule is a hexamer, made up of 3 pairs of homolo gous Aα, Bβ, and γ polypeptide chains connect ed by disulfide bridges that form a central E re gion composed by the N terminal portions of all 6 chains and 2 terminal D regions containing the C terminal fragments of the Bβ and γ chains.
1
The C terminal fragments of the Aα chains form globular structures located near the central E re gion. 1 After cleavage of fibrinopeptides A and B mediated by thrombin, fibrin monomers are formed, which polymerize through the interac tion of the D region with the E regions of subse quent monomers to form protofibrils and through
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Congenital structural and functional fibrinogen disorders: a primer for internists FGA and other affecting Arg301 in exon 8 of FGG. The mechanisms underlying clinical manifesta tions observed in qualitative congenital fibrin ogen disorders involve abnormal formation of a fibrin clot associated with disturbed release of fibrinopeptides, delayed fibrin polymeriza tion or defective cross linking. 4,8,9 A single muta tion altering a fibrinogen chain may result in sig nificant changes in the tertiary and quaternary structure of the protein causing all of the above disorders. 4,8, 9 To date, about 30 different muta tions causing hypodysfibrinogenemia have been identified (10 in the FGA gene, 5 in the FGB gene, and 15 in the FGG gene). Most of these fibrinogen mutations were inherited in an autosomal dom inant manner. 10 Combined heterozygosity was found in additional 7 patients with hypodysfi brinogenemia. 10 In patients with hypodysfibrin ogenemia, the hypofibrinogenemic phenotype re sults from mutation affecting synthesis, assembly, and secretion or leading to an increased fibrino gen clearance, while the dysfibrinogenemic phe notype results from impaired fibrin polymeriza tion and abnormal binding of calcium ions or tis sue plasminogen activator. 10 The first Polish case of dysfibrinogenemia, Fi brinogen Kraków associated with the Asn325Ile mutation in the fibrinogen γ chain and causing hypodysfibrinogenemia with thrombotic man ifestation, was described in 2009. 11 Genetically characterized fibrinogens described for the first time in Polish patients are shown in Clinical manifestations In patients with afibrino genemia, umbilical stump bleeding in newborns is the typical first manifestation of the disease, observed in 85% of cases. 13 Bleeding in afibrino genemia may also commonly occur as nosebleeds and less frequently cutaneous bleeding, gastro intestinal hemorrhage, and genitourinary bleed ing. Intracranial bleeding, often spontaneous, is the most common cause of death in patients with afibrinogenemia.
13 Intramuscular and hemarthro sis also occur in afibrinogenemia, usually less re currently and less damaging than in severe he mophilia, even though severe arthropathies have also been reported in afibrinogenemia.
5 Three ad ditional manifestations are considered specific for afibrinogenemia, namely spontaneous spleen rupture, impaired wound healing, and the forma tion of painful bone cysts.
14 Afibrinogenemia in women is typically associated with spontaneous miscarriages in the first trimester of pregnancy.
13
Other pregnancy related manifestations include pre or postpartum hemorrhages, as well as pla cental abruption. Indeed, fibrinogen ensures pla cental integrity and is necessary for the devel opment of blood vessels in its villi. 13 Over 50% of women with afibrinogenemia have prolonged heavy menstrual bleeding that requires hormonal treatment. 13 Paradoxically, patients with afibrin ogenemia may have thromboembolic events as sociated with or without fibrinogen substitution structure of fibrin, even at lower fibrinogen con centrations, could paradoxically increase throm botic risk by impairing fibrin degradation by plas min or facilitating clot fragmentation. 2,3
Congenital fibrinogen disorders Genetic background
Congenital disorders of fibrinogen is a hetero geneous group of rare abnormalities most of ten caused by mutations in one of the 3 separate genes encoding individual polypeptide chains, located on chromosome 4q28 in a cluster of about 50 kbp (FGA, FGB, and FGG, respectively, for chains Aα, Bβ, and γ, but the order of genes from centromere to telomer is as follows: FGB, FGA, and FGG). 4 So far, over 450 mutations in FGA, FGB, and FGG genes have been registered, of which over 250 are symptomatic (www.geht.org). The most common mutations (50%-80%) are single amino acid missense mutations. Other defects responsible for fibrinogen abnormalities include nonsense mutations, read frame changes through small deletions or insertions in the cod ing part of the gene (frameshift), splicing site mutations, and large deletions. 4 Less than 5% of cases are genetic variants located in the 3' and 5' untranslated regions of the genes. 5 Still, a few patients with severe fibrinogen deficiency have no identified genetic cause, and the use of next generation sequencing can help clarify genetic background of these disorders.
The causative mutations described so far re sult in either qualitative or quantitative fibrino gen disorders. 4 Quantitative disorders are tradi tionally divided into afibrinogenemia (complete absence of fibrinogen) and hypofibrinogenemia (proportionally reduced functional fibrinogen and its antigen levels). 4,6 Afibrinogenemia is in herited in an autosomal recessive manner, while hypofibrinogenemia, dysfibrinogemia, and hy podysfibrinogenemia are autosomal dominant. 4 Afibrinogenemia is due to homozygosity or com pound heterozygosity of a null mutation. 4 It is es timated that quantitative congenital fibrinogen disorder accounts for 8% of rare coagulation fac tor deficiencies. 5 The prevalence of afibrinogen emia is estimated to be 1/1 000 000 or more in some countries where marriage of close relatives is common, for example, in Iran. 4 As hypofibri nogenemias are mainly caused by heterozygosi ty for fibrinogen gene mutation, they are much more frequent than afibrinogenemia.
Qualitative fibrinogen disorders include dys fibrinogenemia (normal amount of dysfunction al fibrinogen) and hypodysfibrinogenemia (de creased amount of dysfunctional fibrinogen). Almost all dysfibrinogenemias are caused by heterozygous missense mutations in FGA and FGG genes. Their prevalence is unknown as they are often asymptomatic. 6 In a recent systemat ic analysis of exome / genome data from about 140 000 individuals of genome databases, it was estimated that their prevalence is up to 0.3% to 1%.
7 Two hotspot mutations are particularly fre quent, one affecting residue Arg35 in exon 2 of and thrombosis was 6 and 13.5 per 1000 adult patient years, respectively. 8 About 25% of pa tients with dysfibrinogenemia reported a mild bleeding tendency.
8, 13 Pregnant women with dys fibrinogenemia can experience recurrent spon taneous miscarriages in the first trimester of pregnancy, placenta abruption, and postpartum thrombosis. 13 In a large patient cohort, approx imately 20% of women experienced postpar tum hemorrhage, and the risk was 6 fold higher in women with previous bleeding phenotype. 14 In about 20% of cases, there is a tendency for venous and / or arterial thrombosis. The most classic example is the Dusart Fibrinogen, due to a single base change (C>T) in the Aα chain gene, resulting in the amino acid substitution Aα 554 Arg>Cys and consequently to the for mation of very thin fibrin fibers with defective plasminogen binding.
15 Dysfibrinogemia is a rare cause of inherited thrombophilia (about 0.8%) 16 as compared with deficiencies of natural anti coagulants, but it cannot be ignored.
17, 18 There is evidence that dysfibrinogenemia can lead to a rare severe complication of pulmonary embo lism such as thromboembolic pulmonary hy pertension.
19 Therefore, an extensive fibrino gen work up is suggested by experts in patients with this type of pulmonary hypertension.
14,20
Prothrombotic mechanisms in dysfibrinogen emia may include reduced binding of thrombin to the abnormal fibrin network, abnormalities in fibrin polymerization with the formation of abnormal clot with tendency to fiber fragmenta tion and impaired fibrinolysis. 13,21 A correlation treatment. Deep vein thrombosis and ischemic stroke are frequent, but thromboses at unusu al arterial and / or venous sites have also been reported.
4,6,13,15
Hypofibrinogenemia is often asymptomatic and diagnosed accidentally, especially when fibrin ogen levels are higher than 1 g/l. 6 In the remain ing patients, the bleeding phenotype predomi nates, depending on the fibrinogen level. Spon taneous bleeding events, such as heavy periods, muscle hematomas, or gastrointestinal bleeding, occur in approximately 20% of patients with hy pofibrinogenemia, especially when plasma fibrin ogen concentrations do not exceed 0.5 g/l.
13 Hy pofibrinogenemias are also associated with an in creased risk of bleeding related to pregnancy, trau ma, or surgery.
6 It should be noted that in rare subtypes of hypofibrinogenemia, fibrinogen ag gregates may accumulate in the endoplasmic re ticulum of hepatocytes, leading to liver storage disease of varying severity.
13
Qualitative fibrinogen abnormalities are re lated to the reduced activity of normal amount of fibrinogen.
8,10 Clinical manifestations are heterogeneous. Approximately 55% of patients are asymptomatic, and about 50% to 60% of patients are diagnosed as part of work up due to prolonged routine clotting times or reduced functional fibrinogen levels, for example, be fore invasive procedures or during hospitaliza tion. 6 Remaining patients can present a bleed ing or / and a thrombotic phenotype. In a large cohort of patients with a median follow up of 6 years, the overall incidence of major bleeding Patients with dysfibrinogenemia (type 3 con genital disorder) are distinguished by: 1 Asymptomatic dysfibrinogenemia or dysfi brinogenemia with bleeding tendencies or occa sional thrombosis (subtype 3A), for which there is no clear association with the genotype 2 Dysfibrinogenemia associated with throm bosis (subtype 3B) found in patients carrying a known mutation increasing the risk of thrombo sis (Fibrinogen Dusart, Caracas V, Ijmuiden, New York I, Nijmegen, Melun, and Naples in a homo zygous form) or in patients with venous throm bosis or at an early age with a positive family his tory of thrombosis in first degree relatives (of the same genotype) with no other known cause of thrombophilia.
The last group of congenital fibrinogen disor ders (type 4) includes patients with hypodysfi brinogenemia classified as: 1 Severe hypodysfibrinogenemia with fibrin ogen antigen of less than 0.5 g/l (subtype 4A) 2 Moderate hypodysfibrinogenemia with fibrin ogen antigen levels between 0.5 and 0.9 g/l (sub type 4B) 3 Mild hypodysfibrinogenemia with fibrino gen antigen levels from 1.0 g/l to a lower limit of the reference range (subtype 4C)
This recent classification 22 did not include pa tients with an inherited fibrinogen Aα chain mu tation that causes amyloidosis and fibrinogen chain deposition in the kidneys because this fi brinogen variant does not affect routine coagu lation screening tests. 23 Regardless of the type of the fibrinogen muta tion found, it is important to note in all patients: age at diagnosis; the circumstances in which the disease was diagnosed; similar abnormali ties or symptoms in the family; and the type of clinical manifestation (hemorrhagic, with major life threatening bleeding, with recurrent throm boembolic events, or with the need for fibrino gen concentrates).
18
Diagnostic work up of congenital fibrinogen disorders Diagnosis of congenital fibrinogen disor ders is difficult due to the availability of a vast range of analytical methods and reagents to as sess the function of blood coagulation and a large number of mutations in the 3 fibrinogen genes leading to different protein concentrations.
4,16
Traditionally, fibrinogen is the only coagulation factor whose potency is expressed in units of concentration (most commonly in clinical prac tice as g/l), rather than in activity units like oth er coagulation factors. The measurements of fi brinogen concentrations are standardized. De creased fibrinogen concentrations should lead to a suspicion of congenital fibrinogen disorders and a further diagnostic evaluation should be per formed. Of note, a concentration of fibrinogen, as an acute phase protein, increases in response to inflammatory diseases, infections, nephrotic between genotype and phenotype is best docu mented for some dysfibrinogenemias, including thrombotic related variants (described below). 5 Hypodysfibrinogenemia is the most rarely re ported congenital disorder of fibrinogen. It is as sociated with symptoms characteristic of both hypofibrinogenemia and dysfibrinogenemia. 10 In case of a discrepancy between reduced activ ity and reduced antigen fibrinogen levels, hypo dysfibrinogenemia should be suspected.
8,10 Post partum hemorrhage and heavy menstrual bleed ings are particularly frequent, which is why this subtype of anomaly is most often described in symptomatic women. 10, 13 The largest literature re view published so far, reporting 51 patients diag nosed with hypodysfibrinogenemia, showed that the cutoff of 0.7 for the ratio of functional concen tration of fibrinogen to its antigen level has a di agnostic sensitivity of 86%. 10 Interestingly, 22% of patients with hypodysfibrinogenemia did not show clinical manifestations at diagnosis, while 45% experienced at least 1 benign hemorrhagic event prior to diagnosis, 30% of of bleedings oc curred during pregnancy, puerperium, and men strual disorders. 10 Overall, 43% of patients in the studied cohort had at least 1 thromboembol ic event with a predominance of venous throm bosis over arterial thrombosis (3:1). 10 Spontane ous bleeding associated with fibrinogen abnor malities usually occurs at functional fibrinogen levels of less than 0.7 g/l.
Classification of congenital fibrinogen disorders
The latest recommendations of the Research Stan dardization Committee at the International Soci ety on Thrombosis and Haemostasis (ISTH) pub lished in 2018 introduced a new classification of fibrinogen disorders and a modified diagnos tic approach to patients with such a suspicion.
22
It has been suggested to classify congenital dis orders in fibrinogen based on the clinical and bi ological (fibrinogen activity, antigen, and geno type) phenotype. 22 Afibrinogenemia (type 1 congenital fibrino gen disorder): 1 Asymptomatic or bleeding patients are clas sified as afibrinogenemia (subtype 1A). 2 Patients with concomitant thromboembol ic events are classified as afibrinogenemia with phenotypic thrombosis (subtype 1B), even if ac companied by hemorrhagic episodes.
Type 2 includes patients with hypofibrinogen emia classified as: 1 Severe hypofibrinogenemia with a function al fibrinogen concentration of less than 0.5 g/l (subtype 2A) 2 Moderate hypofibrinogenemia with a func tional fibrinogen concentration of 0.5 to 0.9 g/l (subtype 2B) 3 Mild hypofibrinogenemia with a functional fi brinogen concentration from 1.0 g/l to the lower limit of the reference range (2C subtype) 4 Familial hypofibrinogenemia with accumula tion of fibrinogen in the liver (fibrinogen storage TT and reptilase time in the presence of con genital fibrinogen disorders are often prolonged, but according to the current ISTH guidelines 22 they should be considered only as additional tests in patients due to the limited diagnostic value. Indeed, even though TT is commonly used by hematologists as a dysfibrinogenemia screen ing test, results in the reference range (with pro longed reptilase time), as well as prolonged TT, still require measurement of functional fibrino gen and its antigen level.
Regardless of the diagnostic algorithm, in or der to establish the definitive diagnosis of in herited fibrinogen disorders, a detailed analy sis of the genes encoding individual fibrinogen chains is necessary. Screening for these abnor malities should be performed in relatives along with the assessment of the relationship between the genotype and the clinical phenotype. 22 It is recommended that in quantitative fibrinogen dis orders, genetic analysis should start by sequenc ing FGA gene (exon 4 and 5), because they often contain mutations associated with protein func tion loss. 29 The next step should be the analysis of less commonly mutated exons (FGA, exon 2; FGB, exons 2 and 6; and FGG, exons 6 and 8) and, if necessary, sequencing of the remaining exons. 29 In dysfibrinogenemia, the first stage of the diagnostic work up should be the screening of exon 2 of the FGA gene and exon 8 of the FGG gene.
29 Next, exon 5 in FGA, exon 2 in FGB, and exons 3 and 5 in FGG should be assessed. 29 How ever, nowadays, the next generation sequenc ing (eg, wholeexome sequencing) is being more cost effective in identifying a causative muta tion in a rare disease. Standard polymerase chain reaction and Sanger sequencing are still useful to confirm the molecular anomaly or for famil ial studies.
Management of bleeding in congenital fibrinogen
disorders Treatment of a or hypofibrinogen emia and sometimes dysfibrinogenemia is to pro vide adequate concentrations of functional fi brinogen for proper hemostasis by using freshly frozen plasma (FFP), cryoprecipitate, or plasma derived fibrinogen concentrate, with the last be ing the best option.
5, 14 Cryoprecipitate and FFP are associated with infusion related adverse re actions, including the risk of fluid overload and transfusion related acute lung injury as a poten tially fatal adverse event.
30 In addition, the use of FFP and cryoprecipitate is associated with the supply of large amounts of other proteins such as fibronectin, von Willebrand factor, fac tor VIII, factor XIII, and macroglobulin.
30 Final ly, both require thawing, which delays the infu sion of the first dose. Clinical studies have shown that the risk of transmitting a pathogen by ad ministering fibrinogen concentrate is negligible.
30
Fibrinogen concentrate infusion can be compli cated by allergic reactions. The formation of an tibodies against this protein have been reported, but without inhibitory effects.
31
syndrome, during pregnancy, during the use of oral hormonal contraceptives, or after surgi cal interventions, making diagnosis even more challenging and sometimes requiring repeated measurements.
1,4
Coagulation tests most commonly used in the diagnostic work up of congenital fibrinogen disorders include: 1) prothrombin time (PT), also automatically expressed in most laboratories as international normalized ratio (INR); 2) activat ed partial thromboplastin time (APTT); 3) throm bin time (TT); 4) assessment of fibrinogen con centration by the von Clauss method. 24 Even a single measurement indicating plas ma fibrinogen concentration of less than1.5 g/l should lead to a more extensive diagnostic work up and, if necessary, genetic testing. The TT assay, which is poorly standardized, has the highest di agnostic sensitivity, although, similarly to PT and APTT, the TT assay has low specificity. 25 The mea surement of PT, APTT, functional concentration of fibrinogen, and the level of its antigen should constitute the first stage of diagnostic work up in a patient suspected of congenital fibrinogen dis orders. 22 Determination of the functional concen tration of fibrinogen by the von Clauss method is based on the measurement of the coagulation time of poor platelet plasma (by mechanical or optical methods) after activation with high con centration thrombin. 26 Antigen levels are usually measured using specific antibodies with detection by immunodiffusion techniques, immunonephe lometry, or immunoturbidimetry. 26 If the measurement of fibrinogen antigen is not available in a given laboratory, the method of choice should be the determination of fibrinogen concentration based on PT (PT derived fibrino gen assay). 26 PT derived fibrinogen is an indirect measurement in which the concentration of func tional fibrinogen can be estimated on the basis of changes in the optical density of plasma, where the difference in optical density is proportion al to the concentration of fibrinogen compared with subsequent dilutions of the standard with known concentration of this protein. 26 Compared with the von Clauss assay, this method is sensi tive to changes in plasma optical density associ ated with slower fibrinopeptide release and for mation of thicker fibrin fibers. 26 Therefore, in pa tients with dysfibrinogenemia, the PT based mea surement of fibrinogen concentrations overesti mates its actual concentration 5 fold compared with the von Clauss assay and thus correlates with protein levels measured by immunological meth ods. 26 It is a common practice to use a cutoff of less than 0.7 for the ratio of fibrinogen measured by the von Clauss assay and the antigen or the PT based method in the diagnosis of dysfibrinogen emia. 19 It should be noted that some variants, for example, fibrinogen Longmont (FGB Arg166Cys) or fibrinogen Bordeaux (FGA Arg439Cys), have an apparent decrease in fibrinogen concentration measured using the PT based method compared with the von Clauss assay.
of fibrinogen concentrate with a close monitoring of peak and trough fibrinogen levels. 34 In wom en with dysfibrinogenemia and history of recur rent miscarriages, fibrinogen supplementation could be considered to achieve a functional con centration of fibrinogen of around 1 g/l. 30 How ever, such a strategy does not guarantee favor able outcomes and the risk of miscarriage, espe cially in the first trimester of pregnancy, remains significant. 30 There are no data showing that he mostasis is still defective after normalization of fibrinogen concentration in dysfibrinogenemia. Postpartum hemorrhage is a frequent complica tion in women with congenital fibrinogen dis orders and should be monitored closely. An in creased postpartum thrombotic risk has been reported. An appropriate thromboprophylaxis should be considered in selected women follow ing childbirth. 30
Management of thrombosis Occurrence of throm bosis in afibrinogenemia is a clinical conundrum. One hypothesis is that the generation of throm bin in a hematoma or during surgery or during pregnancy, without the antithrombin action of fi brin (ie, acting as a trap for circulating thrombin) can lead to strong platelet activation and aggrega tion stimulated by thrombin and endothelial cell injury, which in turn promotes thrombus forma tion and thromboembolic events in both the ve nous and arterial systems.
35 Thrombosis in such patients requires simultaneous supplementation of fibrinogen and administration of anticoagu lants, most often heparins, with close clinical su pervision and laboratory monitoring. Oral direct thrombin inhibitors and antiplatelet agents, in particular vorapaxar, a protease activated recep tor 1 antagonist, might be considered in afibrino genemic patients with recurrent arterial throm boses; however, in most countries, these agents are unavailable and their safety remains contro versial. 36 Besides the few thrombotic related dys fibrinogenemic variants, all dysfibrinogenemias can contribute to an increased thrombotic risk. Heparins, precisely low molecular weight hepa rins, for example, enoxaparin, are the drugs of choice in treatment of thrombosis in such pa tients, as vitamin K antagonists cannot be reli ably monitored with INR. The chromogenic assay of factor X could be used to determine the correct INR value on warfarin in patients with dysfibrin ogenemia, in whom the INR cannot be accurate ly determined due to interference with the fibrin endpoint in the INR assays. 37 The duration of an ticoagulation depends on the type of thrombosis, the familial history, and the overall phenotype of a patient. In view of this potential thrombotic risk, thromboprophylaxis with heparins should be administrated in all clinical settings with an in creased thrombotic risk, 16 in particular during pregnancy and postpartum.
38
Key points for internists Due to the rarity of con genital fibrinogen disorders, internists are often
The patients who require fibrinogen supple mentation should be treated by hematologists trained in the management of bleeding disor ders. To summarize the key concepts for internal medicine specialists, who may encounter such pa tients occasionally, it should be highlighted that the therapeutic goal based on expert opinions and observational studies is to achieve a functional fi brinogen concentration (coagulometric method) of 1 to 1.5 g/l. The value of 1 g/l is currently con sidered the minimal concentration of fibrinogen to maintain the asymptomatic state in most pa tients, based on publication from the European Network of Rare Hemorrhagic Diatheses 32 ; how ever, some experts suggest a lower target concen tration of fibrinogen, that is, 0.5 to 1 g/l. Fibrino gen is administrated either on demand in case of acute bleeding or surgery, or as prophylaxis in pa tients with afibrinogenemia or severe hypofibrin ogenemia to prevent bleeding. Long term prophy laxis is recommended in patients with afibrino genemia and major recurrent bleedings, but such strategy can also be considered in primary pro phylaxis (ie, before occurrence of first bleeding). Usual infusion strategies, according to the type of product, are indicated below: 1 On demand: fibrinogen concentrate, 50 to 100 mg/kg; cryoprecipitate, 15 to 20 ml/kg; FFP, 15 to 30 ml/kg. 5 2 As prophylaxis: fibrinogen concentrate, 30 to 100 mg/kg of bw every week; cryoprecipitate, 1 unit 3 times a week or 3 units every 7 to 10 days. 5 The final dosage should be adjusted individually depending on the frequency of bleedings and their severity. Isolated cases of unsatisfactory hemosta sis with recurrent bleeding at fibrinogen concen trations of more than 1 g/l have been reported. 30 Increased fibrinogen clearance is seen during ma jor bleeding, which requires increased fibrinogen concentrate dosage with close monitoring. In case of acute bleeding, it is recommended to admin ister fibrinogen based at least on daily monitor ing. 30 Tranexamic acid can also be administered in the event of minor bleeding or minor surgery planned in patients with hypofibrinogenemia or dysfibrinogenemia with a bleeding phenotype.
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In women with heavy menstrual bleeding, espe cially with hypofibrinogenemia, hormonal agents should be considered in addition to oral tranexam ic acid during menstrual bleeding.
Management of pregnant women
Pregnancy is a high risk clinical situation in women with con genital fibrinogen disorders, especially in afibrin ogenemia. A multidisciplinary approach including an obstetrician, hematologist, and anesthetist, preferably in a hemophilia center, is of key im portance, and such women should be referred to a hemophilia center at the first contact with an in ternist. In women with afibrinogenemia or severe hypofibrinogenemia, fibrinogen infusion should be started as soon as possible.
33 Increased fibrin ogen clearance is observed in the third trimester of pregnancy, requiring an increase in the dosage available and cheap determination of plasma fi brinogen concentration using a coagulation assay should be considered in patients with bleeding in cluding persistent minor bleeds and heavy men ses, in particular when there is a positive family history. Fibrinogen level measurement should be also considered in pregnancy complications and thrombosis without clear risk factors. A patient suspected of having afibrinogenemia, hypofibri nogenemia, or dysfibrinogenemia, with lower fi brinogen concentrations (without obvious ac quired cause, for example, disseminated intra vascular coagulation or massive acute thrombo sis), should be referred to a specialist hematolo gy center for further diagnostic work up including genetic evaluation and family counselling. Prop er management is effective in most patients who manifest bleeding related to fibrinogen disorders, therefore search for this abnormality should be encouraged. In Poland, like in many lower income countries, congenital fibrinogen disorders are un derdiagnosed and sparsely reported. Efforts to change this situation should be started from in creased awareness of afibrinogenemia, hypofibri nogenemia, or dysfibrinogenemia among gener al practitioners and internists. not aware of such a condition. Patients in whom reduced fibrinogen concentrations are measured should be referred to hematologists for further work up regardless of the presence or absence of any clinical manifestations to establish a defi nite diagnosis. Even if patients with severe fi brinogen disorders are treated in hemophilia centers, internists should recognize signs and symptoms that should require an emergency treatment as well as refer patients and their rel atives suspected of this type of disorders to spe cialized centers. Internists and general practitio ners should endorse the management in coop eration with the hematologist and treat other diseases, for example, influenza or bacterial in fections, in patients with congenital fibrinogen disorders, being knowledgeable about thrombot ic or bleeding risk. In terms of the management of pain, internists should be aware of the fact that nonsteroidal anti inflammatory drugs in hibiting platelet aggregation, for example, aspi rin should be avoided in patients with congen ital fibrinogen disorders and a bleeding pheno type. 39 Thienopirydines should not be used in such patients either. In asymptomatic fibrino gen disorders, the use of antiplatelet agents fol lowing acute myocardial infarction or stroke is initiated and any changes in the therapy should be discussed with a cardiologist and hematol ogist. 40 On the other hand, thrombosis in pa tients with congenital fibrinogen disorders, in particular some dysfibrinogenemias, should be effectively managed and reduced fibrinogen con centrations should not lead to a false assump tion that patients are at high bleeding risk and anticoagulation should be stopped premature ly. Such decisions should be discussed with spe cialists to avoid recurrent thromboembolism. Some general aspects of management and rec ommendation for internists who take care of pa tients with congenital fibrinogen disorders are presented in In afibrinogenemia and severe hypofibrinogenemia, all new symptoms should be considered as bleeding and treated accordingly until additional investigations are performed.
In afibrinogenemia and severe bleeding, all invasive procedures (including venipuncture) should be avoided and performed only upon approval of hematologist.
Nonsteroidal anti -inflammatory drugs should be avoided in patients with a bleeding phenotype and paracetamol should be preferably used.
Hormonal contraception should be suggested in afibrinogenemic women and severe hypofibrinogenemic women with heavy menses.
Annual visit to a hemophilia center should be organized for all patients with fibrinogen disorders.
Thromboprophylaxis should be considered in patients with dysfibrinogenemia according to recommendations of a given hemophilia center.
Surgical procedure and pregnancy management should be performed under the guidance of specialized centers dealing with bleeding disorders
